O0696 Late acute prosthetic joint infections: better outcome when the implant is removed

Marjan Wouthuyzen-Bakker*, Marine Sebillette2, Jose Lomascabeza3, Adrian Taylor3, Eva Benavent Palomares4, Oscar Murillo4, Javad Parvizi5, Noam Shohat5, Javier Cobo Reinoso6, Rosa Escudero Sánchez2, Marta Fernández-Sampedro7, Eric Senneville6, Kaisa Huotari9, José Barbero Allende10, Joaquín Garcia Cañete11, Jaime Lora-Tamayo12, Matteo Carlo Ferrari13, Danguole Vaznaisiene14, Erlangga Yusuf15, Craig Abolttis16, Rihard Trebbe17, Mauro Jose Costa Salles18, Natividad Benito19, Andrea Vila20, Maria Dolores del Toro21, Tobias Kramer22, Sabine Petersdorf23, Vicens Díaz-Brito Fernandez24, Zelinka Kocak Tufan25, Marisa Sanchez26, Cedric Avrileux2, Alex Soriano27

1University Medical Center Groningen, University of Groningen, Medical Microbiology and Infection Prevention, Groningen, Netherlands, 2Rennes University Hospital, Department of Infectious Diseases and Intensive Care Medicine, Rennes, France, 3Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Foundation Trust, Bone Infection Unit, Oxford, United Kingdom, 4IDIBELL-Hospital Universitari Bellvitge, Infectious disease service, Barcelona, Spain, 5Rothman Institute at Thomas Jefferson University Hospital, Philadelphia, United States, 6Hospital Universitario Ramón y Cajal. IRYCIS, Servicio de Enfermedades Infecciosas, Madrid, Spain, 7Hospital Universitario Marques de Valdecilla-IDIVAL, Infectious Diseases Unit, Department of Medicine, Cantabria, Spain, 8University Hospital Gustave Dron Hospital, Department of Infectious Diseases, Tourcoing, France, 9Pañias Hospital, Helsinki University Hospital and University of Helsinki, Inflammation center, Infectious Diseases, Helsinki, Finland, 10Hospital Universitario Principe de Asturias, Department of Internal Medicine, Madrid, Spain, 11IIS-Fundación Jiménez Díaz, Department of Internal Medicine-Emergency, Madrid, Spain, 12Hospital Universitario 12 de Octubre. Instituto de Investigación i+12, Department of Internal Medicine, Madrid, Spain, 13Humanitas Research Hospital and Humanitas University, Department of Prosthetic Joint Replacement and Rehabilitation Center, Milan, Italy, 14Lithuanian University of Health Sciences, Kaunas Clinical Hospital, Department of Infectious Diseases, Kaunas, Lithuania, 15Antwerp University Hospital (UZA), University of Antwerp, Department of Microbiology, Antwerp, Belgium, 16Northern Health, The department of Infectious Diseases, Melbourne, Australia, 17Valdoltra Orthopaedic Hospital, Service for Bone Infections, Ankarar, Slovenia, 18Santa Casa de São Paulo School of Medical Sciences, São Paulo, Brazil, 19Hospital de la Santa Creu i Sant Pau, Institut d’Investigació Biomèdica Sant Pau, Universitat Autònoma de Barcelona, Infectious Diseases Unit, Department of Internal Medicine, Barcelona, Spain, 20Hospital Italiano de Mendoza, Servicio de Infectología, Mendoza, Argentina, 21 Universidad de Sevilla. Instituto de Biomedicina de Sevilla (IBIS), Unidad Clínica de Enfermedades Infecciosas y Microbiología, Sevilla, Spain, 22-24. Nationales Referenzzentrum für Surveillance von nosokomialen Infektionen am Institut für Hygiene und Umweltmedizin Charité-Universitätsmedizin, Berlin, Germany, 25Ankara Yıldırım Beyazıt University, Ataturk Training & Research Hospital, Infectious Diseases and Clinical Microbiology Department, Ankara, Turkey, 26Hospital Italiano de Buenos Aires, Infectious Diseases Section, Internal Medicine Service, Buenos Aires, Argentina, 27Hospital Clinic, University of Barcelona, Service of Infectious Diseases, Barcelona, Spain

Background: At the moment, surgical debridement and implant retention (DAIR) is the first line surgical treatment modality for all acute prosthetic joint infections (PJI). However, recent studies indicate a very high failure rate in late acute PJIs treated with DAIR. The aim of our study was to evaluate treatment outcome in late acute PJIs treated with DAIR versus implant removal.

Materials/methods: In a large multicenter study, patients with late acute PJIs were retrospectively evaluated. Late acute PJI was defined as the development of acute symptoms and signs of PJI more than 3 months after the index surgery. Symptoms present for more than three weeks were excluded.
from the analysis. Failure was defined as: i) the need for prosthesis removal because of persistent or recurrent signs of infection ii) the need for suppressive antibiotic therapy due to persistent signs of infection or iii) death due to the infection.

**Results:** A total of 445 patients were included, including 340 cases treated with DAIR and 105 cases treated with implant removal (one-stage revision in 20 cases (19.0%), two-stage revision in 78 cases (74.3%), and definitive implant removal in 7 cases (6.7%)). Overall treatment failure was 45.0% (153/340) in the implant retention group versus 24.8% (26/105) in the implant removal group (p < 0.001). The significantly higher failure rate in the implant retention group remained after applying 1:1 propensity matching. No difference in failure was observed between one- and two-stage revision (25.0% (5/20) versus 24.4% (19/78), respectively (p 0.95)). The implant retention group had a substantially higher failure rate in relapse of infection (32.7% (50/153) versus 11.5% (3/26), p 0.03) and in the need for antibiotic suppressive therapy (15.7% (24/153) versus 0% (0/26), p 0.03) compared to the implant removal group.

**Conclusions:** Implant removal should be considered as the first line treatment modality in patients with late acute PJI who are at highest risk to fail DAIR.